In this video, Mhairi Copland, MB ChB, PhD, University of Glasgow, Glasgow, UK, discusses current and future treatment approaches for blast-phase chronic myeloid leukemia (BP-CML). Prof. Copland first highlights the importance of continuing to develop and improve treatment options for patients with BP-CML, and then goes on to share some findings from the MATCHPOINT trial (ISRCTN98986889), which evaluated the efficacy of ponatinib in combination with FLAG-IDA chemotherapy in patients with BP-CML. To conclude, Prof. Copland highlights other studies exploring combination approaches in BP-CML and the potential role of CAR-T therapy and antibodies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals.